Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. 2006

Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas (UNICAMP), 13084-971, Campinas, SP, Brazil.

OBJECTIVE To evaluate the prevalence of ovarian cysts in users of two contraceptive implants compared to users of intrauterine contraceptive (IUC). METHODS A total of 344 women were enrolled at 3 months of use of the etonogestrel-releasing implant (Implanon), the levonorgestrel-releasing implant (Jadelle) or the TCu380A IUC. Bimanual pelvic examination and vaginal ultrasound were performed during routine 3-, 6- and 12-month visits of asymptomatic women. Women with ovarian cysts (or enlarged ovarian follicles > or = 25 mm) were assessed weekly until disappearance or reduction of the image [including estradiol (E2) and progesterone (P) measurement], and women with no ovarian enlargement underwent the same evaluation for the same period of time. RESULTS Ovarian cysts were detected in 5.2%, 13.0% and 1.9% of users of Implanon, Jadelle and IUC, respectively, at 3 months. At 6 months of use, prevalence was 7.2%, 8.0% and 2.1%, whereas 12-month rates were 26.7%, 14.6% and 1.2% in the three groups, respectively. E2 levels were significantly higher among users with ovarian cysts than controls. The time until disappearance of the ovarian cyst was similar in all three groups. There were more cases of menorrhagia in users of implants who had ovarian cysts than in those with no ovarian enlargement. CONCLUSIONS The finding of ovarian cysts or enlarged ovarian follicles during the first year of use of Implanon and Jadelle implants is common and transient and should not be interpreted as a pathologic ovarian cyst. No further medical interventions are necessary.

UI MeSH Term Description Entries
D007434 Intrauterine Devices Contraceptive devices placed high in the uterine fundus. Contraceptive Devices, Intrauterine,Contraceptive IUD,Contraceptive IUDs,IUD, Unmedicated,Unmedicated IUDs,Contraceptive Device, Intrauterine,Device, Intrauterine,Device, Intrauterine Contraceptive,Devices, Intrauterine,Devices, Intrauterine Contraceptive,IUD, Contraceptive,IUDs, Contraceptive,Intrauterine Contraceptive Device,Intrauterine Contraceptive Devices,Intrauterine Device,Unmedicated IUD
D010048 Ovarian Cysts General term for CYSTS and cystic diseases of the OVARY. Corpus Luteum Cyst,Corpus Luteum Cysts,Cyst, Corpus Luteum,Cyst, Ovarian,Cysts, Corpus Luteum,Cysts, Ovarian,Ovarian Cyst
D011372 Progestins Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY. Gestagenic Agent,Progestagen,Progestagenic Agent,Progestational Agent,Progestational Compound,Progestational Hormone,Progestogen,Progestogens,Gestagen,Gestagen Effect,Gestagen Effects,Gestagenic Agents,Gestagenic Effect,Gestagenic Effects,Gestagens,Progestagenic Agents,Progestagens,Progestational Agents,Progestational Compounds,Progestational Hormones,Progestin,Progestin Effect,Progestin Effects,Progestogen Effect,Progestogen Effects,Agent, Gestagenic,Agent, Progestagenic,Agent, Progestational,Compound, Progestational,Effect, Gestagen,Effect, Gestagenic,Effect, Progestin,Effect, Progestogen,Effects, Gestagen,Effects, Gestagenic,Effects, Progestin,Effects, Progestogen,Hormone, Progestational
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003271 Contraceptive Agents, Female Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading. Contraceptives, Female,Agents, Female Contraceptive,Female Contraceptive Agents,Female Contraceptives
D004343 Drug Implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug. Drug Implant,Drug Pellet,Pellets, Drug,Drug Pellets,Implant, Drug,Implants, Drug,Pellet, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
December 2010, Journal of pediatric and adolescent gynecology,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
August 2011, Journal of obstetrics and gynaecology of India,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
March 2000, American journal of obstetrics and gynecology,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
June 1995, The Journal of steroid biochemistry and molecular biology,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
January 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
September 2003, Contraception,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
April 2017, The journal of family planning and reproductive health care,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
February 2014, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
November 2004, Contraception,
Maria Margarete Hidalgo, and Claudio Lisondo, and Cássia Teatin Juliato, and Ximena Espejo-Arce, and Ilza Monteiro, and Luis Bahamondes
March 2001, Contraception,
Copied contents to your clipboard!